Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development

Abstract Negative symptoms have long been considered a core component of schizophrenia. Modern conceptualizations of the structure of negative symptoms posit that there are at least two broad dimensions (motivation and pleasure and diminished expression) or perhaps five separable domains (avolition,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gregory P. Strauss, Lisa A. Bartolomeo, Philip D. Harvey
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Psychiatry RC435-571
Acceso en línea:	https://doaj.org/article/6834fb18be19439db326edda7e32bb9b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6834fb18be19439db326edda7e32bb9b
record_format	dspace
spelling	oai:doaj.org-article:6834fb18be19439db326edda7e32bb9b2021-12-02T13:33:05ZAvolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development10.1038/s41537-021-00145-42334-265Xhttps://doaj.org/article/6834fb18be19439db326edda7e32bb9b2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41537-021-00145-4https://doaj.org/toc/2334-265XAbstract Negative symptoms have long been considered a core component of schizophrenia. Modern conceptualizations of the structure of negative symptoms posit that there are at least two broad dimensions (motivation and pleasure and diminished expression) or perhaps five separable domains (avolition, anhedonia, asociality, blunted affect, alogia). The current review synthesizes a body of emerging research indicating that avolition may have a special place among these dimensions, as it is generally associated with poorer outcomes and may have distinct neurobiological mechanisms. Network analytic findings also indicate that avolition is highly central and interconnected with the other negative symptom domains in schizophrenia, and successfully remediating avolition results in global improvement in the entire constellation of negative symptoms. Avolition may therefore reflect the most critical treatment target within the negative symptom construct. Implications for targeted treatment development and clinical trial design are discussed.Gregory P. StraussLisa A. BartolomeoPhilip D. HarveyNature PortfolioarticlePsychiatryRC435-571ENnpj Schizophrenia, Vol 7, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psychiatry RC435-571
spellingShingle	Psychiatry RC435-571 Gregory P. Strauss Lisa A. Bartolomeo Philip D. Harvey Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
description	Abstract Negative symptoms have long been considered a core component of schizophrenia. Modern conceptualizations of the structure of negative symptoms posit that there are at least two broad dimensions (motivation and pleasure and diminished expression) or perhaps five separable domains (avolition, anhedonia, asociality, blunted affect, alogia). The current review synthesizes a body of emerging research indicating that avolition may have a special place among these dimensions, as it is generally associated with poorer outcomes and may have distinct neurobiological mechanisms. Network analytic findings also indicate that avolition is highly central and interconnected with the other negative symptom domains in schizophrenia, and successfully remediating avolition results in global improvement in the entire constellation of negative symptoms. Avolition may therefore reflect the most critical treatment target within the negative symptom construct. Implications for targeted treatment development and clinical trial design are discussed.
format	article
author	Gregory P. Strauss Lisa A. Bartolomeo Philip D. Harvey
author_facet	Gregory P. Strauss Lisa A. Bartolomeo Philip D. Harvey
author_sort	Gregory P. Strauss
title	Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
title_short	Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
title_full	Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
title_fullStr	Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
title_full_unstemmed	Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
title_sort	avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6834fb18be19439db326edda7e32bb9b
work_keys_str_mv	AT gregorypstrauss avolitionasthecorenegativesymptominschizophreniarelevancetopharmacologicaltreatmentdevelopment AT lisaabartolomeo avolitionasthecorenegativesymptominschizophreniarelevancetopharmacologicaltreatmentdevelopment AT philipdharvey avolitionasthecorenegativesymptominschizophreniarelevancetopharmacologicaltreatmentdevelopment
_version_	1718392857648168960

Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development

Ejemplares similares